COHERUS BIOSCIENCES INC (CHRS) Stock News
NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD
CHRS Latest News, Press Relases and Analysis
Which stocks are moving after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025...
Coherus to Participate in Upcoming Investor Conferences
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be...
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily...
Coherus divests Udenyca franchise to Intas for up to $558.4m
Intas’ US speciality division Accord BioPharma has taken responsibility for the franchise in the US.
Mentions: JPM
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus...
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01,...
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology...
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year ––...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and...
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including...
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY,...
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging...
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024...